Eric Francis Yves Thepaut - Feb 14, 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Feb 14, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 04:45 PM
Previous filing
Jan 3, 2023
Next filing
Feb 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Award $0 +7.95K $0.00 7.95K Feb 14, 2023 Common Stock 7.95K Direct F1, F2
transaction BSX Stock Option (Right to Buy) Award $0 +24.8K $0.00 24.8K Feb 14, 2023 Common Stock 24.8K $47.28 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024.
F3 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.